Q-omics provides the consensus-scored DSTNP4 profile across patient tissues and cancer cell-line models. DSTNP4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, DSTNP4 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, DSTNP4 RNA expression shows 6,286 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, BLCA, and STAD as cancer lineages where DSTNP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DSTNP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DSTNP4 survival associations across molecular data types. DSTNP4 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DSTNP4 RNA expression–survival associations across cancer types. High DSTNP4 expression shows unfavorable associations in UVM, STAD, LIHC and THYM, but favorable associations in HNSC and SKCM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for DSTNP4 RNA expression.
This table summarizes DSTNP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for DSTNP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DSTNP4 shows lower tumor expression in BLCA, STAD, UCEC, LUSC and LUAD and higher tumor expression in BRCA. The BLCA box plot shows higher DSTNP4 RNA expression in normal versus tumor tissue (log2 FC = −0.267, t-test p = .003).
This table shows molecular features associated with DSTNP4 in patient tissues and cancer cell lines. In patient samples, DSTNP4 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
